Cognition Therapeutics Shares EEG Insights from CT1812 Study
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company dedicated to developing innovative treatments for neurodegenerative disorders, has recently unveiled important findings from the SEQUEL study of CT1812. This is their leading drug candidate aimed at treating Alzheimer’s disease. The results, published in a respected journal, shed light on how CT1812 influences brain activity in adults suffering from mild to moderate Alzheimer’s disease.
Overview of the SEQUEL Study
The SEQUEL study was a single-site evaluation involving 16 adults diagnosed with mild to moderate Alzheimer’s disease. Participants were given either daily doses of CT1812 or a placebo for 29 days. The primary focus was to analyze the brain's electrical activity using electroencephalography (EEG). This study aimed to evaluate both the safety and effectiveness of CT1812 while also investigating its influence on the brain's electrical impulses.
Key Findings from EEG Measurements
The results from the SEQUEL study indicate that participants treated with CT1812 showed significant improvements in various EEG parameters. Notably, there was a statistically significant reduction in the relative theta power in the central region of the brain (p=0.006), along with changes in AEC-c* (p=0.034), a measure of inter-regional brain connectivity. These findings suggest that CT1812 may help normalize brain wave patterns that are typically disrupted in Alzheimer’s disease.
Understanding Brain Connectivity Changes
Alzheimer's disease is often marked by a gradual decline in brain connectivity and synaptic function, which severely impacts cognitive abilities. The SEQUEL study results demonstrated that treatment with CT1812 not only stabilized global relative theta power but also improved alpha AEC-c measurements, indicating enhanced neural communication. This dual effect highlights the potential neuroprotective benefits of CT1812, suggesting it may aid in restoring essential synaptic activities.
Safety and Tolerability of CT1812
CT1812 has shown to be well tolerated among participants, with treatment-emergent adverse events (TEAEs) occurring at mild to moderate levels. Specifically, mild adverse events were reported in 11 patients receiving CT1812 and in 6 patients taking the placebo, with no severe events leading to discontinuation of treatment. This positive safety profile enhances the potential for CT1812 as a viable therapeutic option for Alzheimer’s treatment.
About CT1812: Mechanism of Action
CT1812 is an orally administered small molecule that selectively targets the sigma-2 (?-2) receptor complex, effectively preventing toxic A? oligomers from harming neurons. The ?-2 receptor is crucial for maintaining cellular integrity, and by focusing on it, CT1812 may reverse cellular damage caused by Alzheimer’s pathology. Preclinical studies support the idea that this binding enhances synaptic function, offering hope for those experiencing cognitive decline.
Future Directions and Studies
Current clinical research includes the START and MAGNIFY studies, which are investigating CT1812’s effects in early Alzheimer’s disease and age-related macular degeneration, respectively. Additionally, Cognition Therapeutics is set to expand its research efforts into other neurodegenerative disorders, including dementia with Lewy bodies.
Contact Information
Cognition Therapeutics, Inc.
Email: info@cogrx.com
Media Contact: Casey McDonald
Tiberend Strategic Advisors, Inc.
Email: cmcdonald@tiberend.com
Investor Contact: Mike Moyer
LifeSci Advisors
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is the SEQUEL study about?
The SEQUEL study investigates the safety and efficacy of CT1812 in adults with mild to moderate Alzheimer’s disease by analyzing brain wave patterns through EEG.
What are the key findings from the SEQUEL study?
The study revealed significant improvements in EEG parameters, especially in brain connectivity and theta power, suggesting potential neuroprotective effects of CT1812.
How well is CT1812 tolerated by patients?
CT1812 was well tolerated, with only mild and moderate treatment-emergent adverse events reported, and no serious complications occurred during the study.
What mechanism does CT1812 employ to combat Alzheimer’s?
CT1812 selectively binds to the sigma-2 receptor to displace toxic A? oligomers, potentially restoring synaptic function and improving cognitive performance.
Are there any ongoing studies involving CT1812?
Yes, Cognition Therapeutics is conducting the START and MAGNIFY studies to explore CT1812's effects in early Alzheimer’s disease and other conditions such as age-related macular degeneration.
